Library / regulatory-reference
France: National Agency for the Safety of Medicines and Health Products (ANSM)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
ANSM, the French National Agency for the Safety of Medicines and Health Products, is France's national regulator for medicines and health products, operating under the Ministry of Health.
France is among Europe's largest medicines markets, and the agency combines authorization, inspection and safety surveillance across drugs, devices, blood products and biological materials.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and the agency also manages early-access schemes for promising treatments before full authorization.
Post-market work includes pharmacovigilance, device vigilance, product-quality inspections and public safety communications to professionals and patients.
Regional and international role
The agency is a major contributor to the European regulatory network, taking frequent rapporteur roles in shared assessments.
Its early-access framework and safety-surveillance scale make it a reference point for balancing speed and oversight.
Using this profile
The authority publishes regulations, registers and alerts in French and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: France illustrates the early-access regulator: structured pre-authorization access alongside large-scale safety surveillance.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.